Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma

被引:21
作者
Tamori, A
Nishiguchi, S [1 ]
Tanaka, M
Kurooka, H
Fujimoto, S
Nakamura, K
Shiomi, S
机构
[1] Osaka City Univ, Dept Hepatol, Grad Sch Med, Osaka 545, Japan
[2] Osaka City Univ, Dept Radiol, Grad Sch Med, Osaka 545, Japan
[3] Osaka City Univ, Dept Nucl Med, Grad Sch Med, Osaka 545, Japan
关键词
hepatitis B e antigen; flare-up; seroconversion;
D O I
10.1016/S1386-6346(03)00002-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We describe a case of hepatitis B virus (HBV) reactivation that responded to lamivudine therapy in a 58-year-old man with advanced hepatocellular carcinoma (HCC). After seroconversion of hepatitis B e antigen to a antibodies by interferon therapy, the patient was found to have HCC with a portal tumor thrombus. A transarterial port was placed in the right femoral artery to permit infusion of epirubicin and cisplatin. After 3 months of arterial chemotherapy, the serum alpha-fetoprotein level had decreased and tumor staining diminished. Laboratory examinations suggested a flare-up of hepatitis B. Lamivudine was given to manage HBV reactivation. After 1 month, the serum HBV DNA level fell below the detection limit, and the alanine aminotransferase activity decreased to the normal range. With further arterial chemotherapy for HCC, no tumor staining was detected on computed tomography. Administration of lamivudine decreased serum HBV DNA levels for 7 months. Our findings suggest that HBV may be reactivated during chemotherapy for HCC, similar to other types of malignancies, and that lamivudine is effective for the management of HBV reactivation. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:77 / 80
页数:4
相关论文
共 26 条
  • [1] Cainelli F, 2001, AM J GASTROENTEROL, V96, P1651
  • [2] Dai MS, 2001, CANCER-AM CANCER SOC, V92, P2927, DOI 10.1002/1097-0142(20011201)92:11&lt
  • [3] 2927::AID-CNCR10109&gt
  • [4] 3.0.CO
  • [5] 2-W
  • [6] Lamivudine as initial treatment for chronic hepatitis B in the United States
    Dienstag, JL
    Schiff, ER
    Wright, TL
    Perrillo, RP
    Hann, HWL
    Goodman, Z
    Crowther, L
    Condreay, LD
    Woessner, M
    Rubin, M
    Brown, NA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) : 1256 - 1263
  • [7] Ikeda K, 1998, CANCER-AM CANCER SOC, V82, P827, DOI 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO
  • [8] 2-G
  • [9] Lamivudine treatment for acute exacerbation of hepatitis B in patients undergoing immunosuppressive therapy
    Kanai, N
    Hasegawa, K
    Ogawa, M
    Naritomi, T
    Hayashi, N
    [J]. HEPATOLOGY RESEARCH, 2002, 22 (03) : 223 - 230
  • [10] Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis
    Kaneko, S
    Urabe, T
    Kobayashi, K
    [J]. ONCOLOGY, 2002, 62 : 69 - 73